Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 17
1999 51
2000 69
2001 149
2002 139
2003 147
2004 221
2005 266
2006 305
2007 324
2008 348
2009 387
2010 434
2011 481
2012 479
2013 530
2014 582
2015 616
2016 554
2017 540
2018 558
2019 315
2020 16
Text availability
Article attribute
Article type
Publication date

Search Results

6,692 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
ABP 980: A Trastuzumab Biosimilar.
Dhillon S. Dhillon S. BioDrugs. 2018 Oct;32(5):511-514. doi: 10.1007/s40259-018-0305-2. BioDrugs. 2018. PMID: 30264234 Review.
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Li BT, et al. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989854 Free PMC article. Clinical Trial.
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF, Vutikullird A, Lawrence TE, Shaw A, Liu MS, Baczkowski M, Sharma R, Barve A, Goyal P, Donnelly C, Sengupta N, Pennella EJ. Waller CF, et al. Br J Clin Pharmacol. 2018 Oct;84(10):2336-2343. doi: 10.1111/bcp.13689. Epub 2018 Jul 31. Br J Clin Pharmacol. 2018. PMID: 29926514 Free PMC article. Clinical Trial.
PF-05280014: A Trastuzumab Biosimilar.
Paik J. Paik J. BioDrugs. 2018 Oct;32(5):515-518. doi: 10.1007/s40259-018-0308-z. BioDrugs. 2018. PMID: 30280367 Review.
[Trastuzumab and its biosimilars].
Sarosiek T, Morawski P. Sarosiek T, et al. Pol Merkur Lekarski. 2018 May 25;44(263):253-257. Pol Merkur Lekarski. 2018. PMID: 29813044 Review. Polish.
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Murthy R, et al. Lancet Oncol. 2018 Jul;19(7):880-888. doi: 10.1016/S1470-2045(18)30256-0. Epub 2018 May 24. Lancet Oncol. 2018. PMID: 29804905 Clinical Trial.
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G; PERTAIN Study Group. Rimawi M, et al. J Clin Oncol. 2018 Oct 1;36(28):2826-2835. doi: 10.1200/JCO.2017.76.7863. Epub 2018 Aug 14. J Clin Oncol. 2018. PMID: 30106636 Clinical Trial.
6,692 results
Jump to page